ItemFurther evaluation of a rapid diagnostic test for melioidosis in an area of endemicity(2004) O'Brien, Matthew J; Jacups, Susan P; Cheng, Allen C; Currie, Bart John; Freeman, Kevin; Lum, Gary ItemCommunity-acquired pneumonia in northern Australia: low mortality in a tropical region using locally-developed treatment guidelines(2005) Elliott, Julian; Anstey, Nicholas Mark; Jacups, Susan P; Fisher, Dale; Currie, Bart John ItemMelioidosis: epidemiology, pathophysiology, and management(2005) Cheng, Allen C; Currie, Bart John ItemAustralian and Thai isolates of Burkholderia pseudomallei are distinct by multilocus sequence typing: revision of a case of mistaken identity(2007) Currie, Bart John; Ward, Linda Maree; Thomas, Annette D; Godoy, Daniel; Dance, David A B; Cheng, Allen C; Mayo, Mark J; Pitt, Tyrone L; Spratt, Brian G ItemScabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance.(2008) Walton, Shelley F; Currie, Bart John; Mounsey, Kate E; Holt, Deborah C; McCarthy, James ItemThe relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria.(2008) Lee, Sue; Stepniewska, Kasia; Anstey, Nicholas Mark; Ashley, Elizabeth; Barnes, Karen; Binh, Tran Quang; D'Alessandro, Umberto; Day, Nicholas P J; de Vries, Peter J; Dorsey, Grant; Guthmann, Jean-Paul; Mayxay, Mayfong; Newton, Paul N; Nosten, Francois; Olliaro, Piero; Osario, Lyda; Pinoges, Loretxu; Price, Richard; Rowland, Mark; Smithuis, Frank; Taylor, Robert; White, Nicholas James ItemGenetic diversity of Burkholderia pseudomallei Isolates in Australia(2008) Spratt, Brian G; Ward, Linda Maree; Currie, Bart John; Godoy, Daniel; Norton, R; Mayo, Mark J; Gal, Daniel; Cheng, Allen C ItemComparison of growth and lipid content in three Botryococcus braunii strains(2005) Li, Yan; Qin, Jianguang ItemIsolates of Burkholderia pseudomallei from Northern Australia are distinct by multilocus sequence typing, but strain types do not correlate with clinical presentation(2004) Cheng, Allen C; Mayo, Mark J; Gal, Daniel; Currie, Bart John; Godoy, Daniel; Spratt, Brian G ItemFirst documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei(2004) Currie, Bart John; Walton, Shelley F; Harumal, P; McKinnon, M ItemGroup A streptococci from a remote community have novel multilocus genotypes but share emm types and housekeeping alleles with isolates from worldwide sources(2004) Currie, Bart John; Carapetis, Jonathan R; Beall, Bernard; Bennett, Alicia; Bessen, Debra E; Bilek, Nicole; Kalia, Awdhesh; McGregor, Karen F; Spratt, Brian G; Sriprakash, Kadaba S ItemProblems in diagnosing scabies, a global disease in human and animal populations.(2007) Currie, Bart John; Walton, Shelley F ItemRole of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection(2008) Thammawat, Sutthiwan; Sadlon, Tania; Hallsworth, Peter Gordon; Gordon, David Llewellyn ItemComparison of nasal swabs with nose blowing for community-based pneumococcal surveillance of healthy children.(2008) Morris, Peter Stanley; Stubbs, Elizabeth; Beissbarth, Jemima; Hare, Kim; Leach, Amanda Jane ItemDevelopment and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei(2006) Novak, Ryan T; Glass, Mindy B; Gee, Jay E; Gal, Daniel; Mayo, Mark J; Currie, Bart John; Wilkins, Patricia P ItemAnalysis of the first Australian strains of Bartonella quintana reveals unique genotypes(2007) Woolley, Mark; Wetherall, Bruce Lawrence; Gordon, David Llewellyn ItemBurkholderia pseudomallei strain type, based on pulsed-field gel electrophoresis, does not determine disease presentation in melioidosis(2005) Day, Nicholas P J; Mayo, Mark J; Gal, Daniel; Currie, Bart John; Cheng, Allen C ItemOutcomes of patients with melioidosis treated with meropenem(2004) Fisher, Dale; Stephens, Dianne Patricia; Jacups, Susan P; Anstey, Nicholas Mark; Cheng, Allen C; Currie, Bart JohnMelioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenemtreated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.